Blog
Fentanyl Trends in Workplace Drug Testing: What Employers Need to Know in 2026
Fentanyl workplace drug testing is handled differently under federal-agency, Department of Transportation and employer-authority programs. As of August 30, 2026, fentanyl is included in the HHS-authorized federal workplace drug-testing panel, but it is not yet included in the current DOT Part 40 panel. Non-DOT employers may be able to add fentanyl testing under a properly written workplace policy and applicable state and local laws.
A rapid fentanyl test cup or strip provides a preliminary screening result. It cannot replace an official DOT test, and a non-negative screening result should be sent for appropriate laboratory confirmation before a significant employment decision is made.
Is Fentanyl Included in Workplace Drug Testing?
The answer depends on which testing program applies to the employee.
| Testing program | Current fentanyl status | Can a rapid test be the official test? |
|---|---|---|
| Federal-agency workplace testing | Fentanyl is included in the HHS-authorized panel effective July 7, 2025 | No. The federal program uses regulated laboratory procedures |
| DOT-regulated testing | Fentanyl and norfentanyl were proposed but are not yet part of the current required DOT panel | No. Point-of-collection and instant tests are not authorized for official DOT testing |
| Non-DOT workplace testing | An employer may be able to include a fentanyl-specific panel when permitted by its policy and applicable law | A rapid test may provide a preliminary result but should not be treated as definitive |
| Federal contractor or grantee workplace | The Drug-Free Workplace Act does not by itself create a universal fentanyl-testing mandate | Testing requirements depend on other applicable rules, contracts and employer policies |
Current Fentanyl Workplace Testing Statistics
The latest workplace data show that fentanyl remains relevant even though the most recent positivity rate moved downward.
The 2026 Quest Diagnostics Drug Testing Index, based on testing performed during 2025, reported that:
- Fentanyl positivity in the general U.S. workforce declined 49.1% year over year.
- The reported rate decreased from 0.55% in 2024 to 0.28% in 2025.
- Overall workforce urine drug-test positivity remained at 4.3% in 2025.
- The report analyzed workplace testing performed through Quest Diagnostics and should not be interpreted as representing every U.S. employee.
This is an important correction to older claims that fentanyl workplace positivity was continuing to increase. Employers should use current data, local risk information and applicable legal requirements when deciding whether to include fentanyl in a non-DOT panel.
Federal Workplace Fentanyl Testing
The Department of Health and Human Services added fentanyl to its authorized federal workplace drug-testing panels effective July 7, 2025. The change applies to federal-agency workplace testing conducted under the HHS Mandatory Guidelines.
The HHS authorized drug-testing panels include fentanyl for urine and oral-fluid testing and norfentanyl as a urine confirmation analyte.
HHS Fentanyl Cutoff Concentrations
| Specimen | Initial test | Initial cutoff | Confirmation analyte | Confirmation cutoff |
|---|---|---|---|---|
| Urine | Fentanyl | 1 ng/mL | Fentanyl | 1 ng/mL |
| Urine | Fentanyl | 1 ng/mL | Norfentanyl | 1 ng/mL |
| Oral fluid | Fentanyl | 4 ng/mL | Fentanyl | 1 ng/mL |
These are HHS federal laboratory cutoffs. They should not be copied onto a commercial rapid-test product page unless that product’s instructions for use specify the same specimen, analyte and cutoff.
Federal Employee Testing Is Not the Same as Contractor Compliance
Federal-agency employee testing should not be confused with the obligations imposed on covered contractors and grant recipients by the Drug-Free Workplace Act.
The Drug-Free Workplace Act generally requires covered organizations to maintain specified policies, awareness programs, notifications and responses. The Act does not create a universal requirement to drug-test every employee or automatically require fentanyl testing.
Is Fentanyl Included in the DOT Drug Test?
No. As of August 30, 2026, fentanyl is not part of the current DOT-required drug-testing panel.
Under the current DOT program, laboratories test for five drugs or drug classes:
- Marijuana metabolites
- Cocaine metabolites
- Amphetamines
- Opioids currently authorized by Part 40
- Phencyclidine, or PCP
The opioid portion currently includes specified opiates and semi-synthetic opioids, but it does not automatically include fentanyl simply because fentanyl is an opioid.
Employers can review the current DOT drug-test requirements and cutoff levels before making changes to a regulated testing program.
What Did DOT Propose?
On September 2, 2025, DOT published a proposed rule that would add fentanyl to its urine and oral-fluid panels and norfentanyl to urine testing. The proposal was intended to harmonize DOT testing with the HHS federal workplace panel.
The proposal can be reviewed in the Federal Register notice concerning the addition of fentanyl to the DOT panel.
A proposed rule is not the same as a final effective rule. Employers should not advertise, order or administer a “new DOT fentanyl test” unless DOT publishes a final rule and its effective date has arrived.
Can a DOT Employer Add Fentanyl to a DOT Specimen?
No. A DOT specimen cannot be tested for drugs that are not currently authorized by Part 40.
Under 49 CFR Section 40.13, DOT and non-DOT tests must remain completely separate. The DOT test must be completed before a separate non-DOT test begins, and the same DOT specimen cannot simply be expanded to include fentanyl.
A DOT-regulated employer may be able to establish a separate employer-authority or non-DOT testing program when permitted by the applicable DOT agency rules, company policy, collective bargaining obligations and state or local law.
The separate program should use:
- A separate specimen collection
- Separate documentation
- A non-DOT testing form
- A clearly identified non-DOT policy
- Appropriate confirmation and review procedures
A non-DOT result cannot replace, cancel or modify an official DOT result.
Can a Rapid Fentanyl Test Cup Be Used for DOT Testing?
No. A rapid fentanyl cup, strip, dip card or oral-fluid device cannot be used as the official DOT drug test.
DOT Section 40.210 states that point-of-collection urine tests, point-of-collection oral-fluid tests, hair tests and instant tests are not authorized for DOT testing.
Official DOT specimens must be screened and confirmed by an appropriate HHS-certified laboratory using required federal procedures, documentation and Medical Review Officer oversight.
DOT regulations authorize oral fluid as a specimen type, but implementation requires at least two HHS-certified oral-fluid laboratories. DOT’s certified oral-fluid laboratory page currently lists no certified laboratories.
Non-DOT Fentanyl workplace drug testing
Non-DOT employers generally have greater flexibility when selecting a drug-testing panel. However, that flexibility does not eliminate legal and procedural requirements.
Before adding fentanyl, an employer should review:
- State and local workplace drug-testing laws
- The written drug-free workplace policy
- Required employee and applicant notices
- Collective bargaining agreements
- Testing reasons permitted by law
- Specimen collection and chain-of-custody procedures
- Laboratory confirmation requirements
- Medical review and prescription-verification procedures
- Rules governing disciplinary or hiring decisions
Employers can review our drug-testing laws by state guide and broader workplace drug-testing compliance requirements. These resources are informational and do not replace advice from qualified legal counsel.
Does a Standard Opioid Test Detect Fentanyl?
Employers should not assume that an OPI, MOP or general opioid panel detects fentanyl.
Traditional opiate immunoassays are commonly designed around morphine, codeine or related metabolites. Fentanyl is chemically different and normally requires a test specifically designed and labeled for fentanyl or its metabolite.
| Label | Common meaning | Should fentanyl detection be assumed? |
|---|---|---|
| OPI or MOP | Traditional opiates such as morphine and codeine | No |
| OXY | Oxycodone and related metabolites | No |
| 6-AM | Heroin metabolite | No |
| FEN or FYL | Commercial fentanyl screening designation | Verify the product instructions and analyte |
| FENT | Federal reporting abbreviation for fentanyl | Yes, within the applicable federal laboratory panel |
| NFENT | Federal reporting abbreviation for norfentanyl | Yes, when specifically included as an analyte |
For a broader explanation, review our guide to how fentanyl is detected in drug testing.
Rapid Screening Versus Laboratory Confirmation
Rapid workplace tests are screening tools. Their results should be described as negative or preliminary non-negative rather than as definitively positive.
| Rapid screening | Laboratory confirmation |
|---|---|
| Provides an initial qualitative result | Uses validated analytical testing to identify specific analytes |
| May be performed at the point of collection when permitted | Performed by an appropriate laboratory |
| Does not establish impairment | Confirms the presence of the reported drug or metabolite at the applicable cutoff |
| Cannot serve as an official DOT test | Required as part of the regulated DOT process |
| A non-negative result requires further action under the policy | May be followed by Medical Review Officer review when applicable |
A confirmed fentanyl result does not by itself establish when the substance was used, the dose taken or whether the employee was impaired at a specific time.
Steps for Adding Fentanyl to a Workplace Testing Program
- Determine whether each employee is covered by DOT, federal-agency or non-DOT rules.
- Keep DOT and non-DOT testing programs completely separate.
- Review state laws, local ordinances, contracts and collective bargaining requirements.
- Update the written policy before implementing a new fentanyl panel.
- Provide legally required employee or applicant notice.
- Select a test that specifically identifies fentanyl and states the intended specimen, cutoff and use.
- Verify the product’s FDA clearance, CLIA status or forensic-use designation when those classifications are relevant.
- Document collection, custody, storage and result-review procedures.
- Send preliminary non-negative results for appropriate laboratory confirmation.
- Use qualified review and legal guidance before taking a significant employment action.
- Monitor DOT and HHS publications for future rule changes.
Selecting a Fentanyl Test for Non-DOT Screening
Employers using an appropriate non-DOT program can compare fentanyl testing products and expanded multi-panel urine drug-test cups.
Before ordering, verify:
- Whether the product is intended for urine, oral fluid or substance checking
- Whether it detects fentanyl, norfentanyl or another specified analyte
- The stated cutoff concentration
- The product’s intended-use designation
- Whether it is CLIA waived, non-waived or Forensic Use Only
- The result-reading time stated in the instructions
- The procedure for sending non-negative specimens for confirmation
Do not select a product solely because its panel count is higher. The fentanyl analyte must be specifically listed in the product configuration.
Key Takeaways for Employers
- HHS added fentanyl to its authorized federal workplace panel effective July 7, 2025.
- The HHS federal-agency panel is not the same as the DOT panel.
- As of August 30, 2026, fentanyl is still not part of the current required DOT panel.
- DOT’s September 2025 fentanyl rule remains a proposal until a final effective rule is published.
- A DOT specimen cannot be expanded to include unauthorized drugs.
- Any additional employer-authority test must be conducted as a separate non-DOT test.
- Rapid tests cannot replace an official DOT laboratory test.
- A preliminary non-negative result should receive appropriate laboratory confirmation.
- A drug-test result does not by itself establish impairment.
Frequently Asked Questions
Is fentanyl included in the DOT drug test in 2026?
No. As of August 30, 2026, fentanyl is not included in the current required DOT Part 40 panel. DOT proposed adding fentanyl and norfentanyl, but the proposal has not yet become a final effective rule.
Is fentanyl included in federal workplace drug testing?
Yes. HHS added fentanyl to its authorized federal workplace drug-testing panels effective July 7, 2025. This applies to covered federal-agency testing programs and does not automatically require every private employer or federal contractor to test for fentanyl.
Does a standard opioid drug test detect fentanyl?
Fentanyl should not be assumed to be included in a standard OPI, MOP or oxycodone test. Employers should select a panel that specifically lists fentanyl and verify the intended analyte in the product instructions.
Can a DOT employer add fentanyl to a DOT specimen?
No. DOT specimens cannot be tested for unauthorized additional drugs. If legally permitted, an employer may establish a separate non-DOT program using a separate collection, documentation and policy.
Can a rapid fentanyl test cup be used as an official DOT test?
No. DOT does not authorize point-of-collection urine tests, point-of-collection oral-fluid tests or instant tests as official DOT drug tests.
What are the HHS federal fentanyl cutoffs?
For urine, the HHS initial fentanyl cutoff is 1 ng/mL, with confirmation cutoffs of 1 ng/mL for fentanyl and 1 ng/mL for norfentanyl. For oral fluid, the initial fentanyl cutoff is 4 ng/mL and the confirmation cutoff is 1 ng/mL.
Does a positive fentanyl test prove impairment?
No. A drug-test result identifies a drug or metabolite under the applicable testing procedure. It does not by itself establish the timing of use, the dose taken or impairment at a particular moment.
What should an employer do after a preliminary non-negative fentanyl result?
The employer should follow its written policy, maintain specimen and documentation integrity, obtain appropriate laboratory confirmation and use qualified review before making a significant employment decision.
